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Abstract
B a ckg round : A t present, women w ith threatened preterm labor before 32 weeks o f gestation 
are, after transfer to  a perinatal center, treated w ith tocolytics and corticosteroids. Many o f these 
women are treated unnecessarily. Fibronectin is an accurate predictor fo r the occurrence of 
preterm birth among women w ith threatened preterm labor. W e w ill assess whether triage of 
these women w ith fibronectin testing, cervical length o r  the ir combination is cost-effective.
M e th ods /D es ign : W e w ill investigate a prospective cohort o f women referred to  a perinatal 
centre fo r spontaneous threatened preterm labor between 24 and 34 weeks w ith intact 
membranes. A ll women will be tested fo r fibronectin and cervical length. W omen w ith a cervical 
length <10 mm and women w ith a cervical length between 10-30 mm in combination w ith a positive 
fibronectin test w ill be treated w ith tocolytics according to  local protocol. W omen w ith a cervical
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length between 10-30 mm in combination w ith a negative fibronectin test w ill be randomised 
between treatment w ith nifedipine (intervention) and placebo (control) fo r 48 hours. W om en w ith 
a cervical length > 30 mm w ill be managed according to  local protocol. Corticosteroids may be 
given to  all women at the discretion o f the attending physician. Primary outcome measure w ill be 
delivery w ithin 7 days. Secondary outcome measures w ill be neonatal m orbidity and mortality, 
complications o f tocolytics, costs and health related quality o f life. The analysis w ill be according to  
the intention to  trea t principle. W e anticipate the probability on preterm birth w ithin 7 days in the 
group o f women w ith a negative fibronectine test to  be 5%. Two groups o f 110 women w ill be 
needed to  assure that in case o f non-inferiority the difference in the proportion o f preterm 
deliveries < 7 days w ill be w ithin a prespecified boundary o f 7.5% (one sided test, P 0.2, a  0.05). 
Data obtained from women w ith a positive and negative fibronectin tests in both the cohort study 
and the tria l w ill be integrated in a cost-effectiveness analysis that w ill assess economic 
consequences o f the use o f fibronectin.
D iscussion: This study w ill provide evidence fo r the use o f fibronectin testing as safe and cost- 
effective method in a triage fo r threatened preterm labor.
T r ia l re g is tra tio n : Nederlands Trial Register (NTR) number 1857, http://www.trialregister.nl.
Background
Preterm birth is the most frequent cause of perinatal m or­
tality and severe perinatal morbidity in the Western world 
[1 ]. Preterm birth can be preceded by rupture of the mem­
branes and/or by uterine contractions leading to cervical 
effacement and dilation. Current treatment of women 
with threatened preterm labor is tocolysis to diminish 
contractions and the administration of corticosteroids to 
enhance fetal lung development [2]. In the Netherlands, 
7.9% of all deliveries are preterm, and 1.6% of all 
neonates are born before 32 weeks of gestation [3]. 
Women at risk for preterm birth prior to 32 weeks are 
transferred to a perinatal centre [4].
Discriminating those women who will deliver preterm is 
difficult: about half of the women treated with tocolytics 
and/or corticosteroids do not deliver within a short time 
after the occurrence of symptoms. As tocolytics and corti­
costeroids can cause severe side-effects in both mother 
and child [5-8], concerns have been expressed about over­
treatment. If we are able to identify women that eventu­
ally do not deliver preterm and thus do not benefit from 
referral and treatment, we could prevent them from being 
exposed to the potential side effects of tocolytics and cor­
ticosteroids. In addition, management costs could be 
reduced by preventing unnecessary transport of pregnant 
women to perinatal centers and the associated higher 
treatment costs.
Fetal fibronectin is an internationally accepted predictor 
of preterm birth [9]. Fetal fibronectin is a glycoprotein 
found in amniotic fluid, placental tissue, and the extracel­
lular substance of the decidua next to the placental inter­
villous space. It is thought to be released through 
mechanical or inflammatory mediated damage to the
membranes or placenta before birth [10]. Swabs can be 
taken from the ectocervix or posterior vaginal fornix, and 
an enzyme linked im munosorbent assay (ELISA) contain­
ing FDC6 monoclonal antibody can be used to detect fetal 
fibronectin [11]. The results may indicate the likelihood 
of spontaneous preterm birth [12]. In clinical use, how­
ever, factors such as contamination of the sample with 
maternal blood, sampling within 24 hours after inter­
course, and preeclampsia may reduce the accuracy of the 
test and give false positive results [13-15].
The predictive capacity of fibronectin has been the topic of 
previous studies. Honest and co-workers published in 
2002 a systematic review on the predictive capacity of 
fibronectin for preterm delivery [16]. They identified 40 
studies reporting on symptomatic women. The summary 
likelihood ratio for a positive result was 5.4 (95% CI 4.4 
to 6.7) for predicting birth within 7 to 10 days of testing, 
with a corresponding likelihood ratio for a negative result 
of 0.25 (95% CI 0.20 to 0.31). Therefore fibronectin test­
ing might be able to reduce unnecessary treatment and 
subsequent costs. On the other hand, introducing 
fibronectin tests has not yet proven to reduce health care 
costs if the subsequent management is subject to physi­
cians preferences [17-21]. In addition, high false positive 
rates may increase health care costs in the management of 
low risk women.
For cervical length measurement, the situation is different. 
This test is shown to predict preterm delivery in asympto­
matic women at 20 weeks [22]. However, the accuracy of 
the test is only marginally evaluated in women with symp­
toms of preterm labor at a later gestational age [23]. 
Gomez et al. evaluated the predictive accuracy of a combi­
nation of fetal fibronectin measurement and cervical
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length measurement [24]. In their study, 15% of the 
women had cervical lengths below 15 mm, and one third 
of these women delivered within 48 hours. Among those 
with a cervical length between 15 mm and 30 mm (36% 
of the population), 25% had a positive fibronectin test, 
and 15% of this group delivered within 48 hours. O f the 
remaining 75% of the women, less than 5% delivered 
within 7 days. These results are comparable with our pilot 
study of Wilms et al. Amongst 19 women with a cervical 
length between 10-30 mm and a negative fibronectin test, 
only 1 woman delivered within 7 days[25].
At present, fibronectin testing is not routinely used in The 
Netherlands. To assess the risk for threatened preterm 
labor, only cervical length is routinely measured[2]. This 
measurement is frequently used as an argument to trans­
fer and treat women for threatened preterm labor, even if 
clinical symptoms are mild. Identifying women that are at 
high risk for preterm delivery could benefit from adding 
fibronectin testing. Therefore we will evaluate if adding 
fibronectin testing to cervical length measurement is a safe 
and cost-effective strategy as a triage for women with 
threatened preterm labor.
Methods/Design
Aims
We will evaluate a risk assessment with fibronectin testing 
for women with clinical signs of threatened preterm labor. 
We will assess whether triage of these women with 
fibronectin testing, cervical length measurements or a 
combination is cost-effective. The results of this study can 
be used to support a policy of expectant management 
without immediate referral to a neonatal centre and with­
out tocolysis in women with a low risk for preterm birth.
Participants/eligibility criteria
All women between 24 and 34 weeks of gestational age 
with primary complaints associated with preterm labor 
and intact membranes will be eligible for inclusion in the 
study. Women with vaginal bleeding, a cerclage, cervical 
dilatation of more than 3 cm or previous treatment for 
threatened preterm labor in the current pregnancy are 
excluded. Other exclusion criteria are hypertension, con­
tra indications for nifedipine and fetal distress or maternal 
conditions that may lead to pregnancy termination within 
7 days. The study will be limited to women admitted to a 
perinatal centre with neonatal intensive care facilities.
Procedures, recruitment, randomisation and collection o f  
baseline data
Women meeting the eligibility criteria will be informed 
and invited to participate in the study and asked for writ­
ten informed consent. At study entry baseline demograph­
ics, obstetric and medical history will be recorded. Before 
cervical length measurement, women will be tested for
fibronectin. Therefore a sample of cervicovaginal secre­
tion will be taken by rotating a swab in the posterior vag­
inal fornix for 10 seconds. Analysis will be performed 
using the FullTerm TLijq system of Hologic [26].
Women with a cervical length below 10 mm and women 
with a cervical length between 10-30 mm in combination 
with a positive fibronectin test will be treated with tocoly­
sis. These women are considered to be at high risk for pre­
term delivery. Women with a cervical length above 30 mm 
will be treated according to the discretion of the physi­
cian. Women with a cervical length between 10-30 mm 
and a negative fibronectin test are considered to be at low 
risk, they will enter a double blind trial in which they will 
be randomised by a central web-based system between 
tocolytics or placebo (1:1). Details of delivery and mater­
nal assessments during pregnancy of all women are 
recorded in case record forms (CRF) that are accessible 
through a closed part of a central website. All data will be 
collected, coded and processed with adequate precautions 
to ensure patient confidentiality.
Interventions
All high risk women will receive tocolytics according to 
local protocol. Fibronectin negative women with a cervi­
cal length between 10-30 mm will be randomly allocated 
to tocolytics or placebo (figure 1). Active treatment will be 
performed with the calcium channel blocking agent nifed­
ipine with a total daily dose between 80 and 120  milli­
grams for 48 hours. Active drug and placebo will be 
administered orally at the same volume and rate. Corti­
costeroids will be administered at the discretion of the 
attending physician.
Progression of labor will be monitored every 12 hours by 
means of clinical observation and/or vaginal examina­
tions for 48 hours. If labor seems inevitable in that period, 
study medication can be stopped and another tocolytic 
(excluding nifedipine) may be administered.
Follow up o f women and infants
Details of admission of newborns to the neonatal inten­
sive care unit and neonatal complications will be 
recorded. Long term follow up is not part of this study.
Outcome measures
The primary outcome measure is num ber of days to deliv­
ery truncated at 7 days after study entry. Secondary end­
points are neonatal mortality, neonatal morbidity, 
maternal morbidity (side effects of nifedipine), costs and 
health related quality of life.
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GA 24-34 weeks 
Sympt. preterm labor 
Intact membranes
F ig u re !
F lo w  c h a r t A P O S T E L -I s tudy , an o v e rv ie w  o f w h ich  p a tie n ts  in  th e  A P O S T E L -I c o h o r t w il l  be ra n d o m ize d  
based on th e ir  ce rv ica l le n g th  and f ib ro n e c t in  status.
Statistical issues
Sam ple size
The randomised trial in our study will be a non-inferiority 
effectiveness trial. Based on our pilot study [25], we antic­
ipate the probability on preterm birth within 7 days in the 
group of women with a negative fibronectine test and a 
cervical length 10-30 mm to be 5%. We need 220 
fibronectin negative women in the cohort ( 1 1 0  per arm) 
to assure with 80% power that in case of non-inferiority 
the upper limit of the 95% one-sided CI for the difference 
in the proportion of preterm deliveries < 7 days will be 
within a prespecified boundary of 7.5%. According to our 
pilot we will need a cohort of approximately 660 women
[25].
Data analysis
The results of the randomised trial will be analyzed 
according to the intention to treat principle. We will ana­
lyze costs and effects of a strategy based on fibronectin 
measurement and cervical length, in which only fibronec- 
tin positive women will be transferred to a perinatal center 
and/or and treated. Costs and effects of this strategy will 
be compared to a strategy in which these women will be 
transferred and treated merely based on a clinical diagno­
sis by e.g. vaginal examination and/or cervical length 
measurement.
Interim analysis
After 100 fibronectin negative, low risk women have 
entered the randomised trial, an interim analysis will be
performed by an external independent safety committee. 
Interim analysis will be performed on the primary out­
come only, e.g. percentage of preterm deliveries within 7 
days after fibronectin testing. If there is a significant differ­
ence between the groups treated with tocolytics and pla­
cebo, the independent safety committee will decide about 
further unblinding of the interim results and (d iscon tin ­
uation of the trial.
Economic evaluation
The aim of the economic evaluation is to assess whether 
fibronectin testing as a triage for women with threatened 
preterm labor is cost-effective. For the cost analysis we dis­
tinguish cost within the antenatal period, during delivery 
and childbirth and within the postnatal period. As the 
study will be performed from a societal perspective, three 
cost categories will be included: direct medical costs, 
direct non-medical costs and indirect costs. Volumes of 
health care resource use during the index admission are 
measured prospectively alongside the clinical study in all 
participating centers as part of the CRF. Questionnaires 
addressing health related quality of life will be adminis­
tered in a random subsample.
If the randomised trial indicates that a particular sub­
group of women does not benefit from treatment with 
tocolytics, the economic analysis will be a cost-minimiza- 
tion analysis. If tocolysis and transferring low risk women 
would not be necessary, the costs of risk assessment 
(int.al. fibronectin testing) of the whole cohort of women
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will be compared to the potential cost saving. Further­
more, scenario analyses for relevant subgroups will be 
performed. Before analyzing the data from the study, a 
detailed cost analysis model will be developed.
The trial results will be incorporated in a diagnostic model 
to compare a risk assessment strategy for women with 
threatening preterm labor within current practice, which 
does not include additional risk assessment with fibronec- 
tin.
The study design will enable us to compare the costs and 
effects of the following strategies:
I. transfer and treat all women with threatening preterm 
labor
II. transfer and treat women based on the results of 
fibronectin measurement. As we also measure cervical 
length, we can also evaluate the following strategies:
III. transfer and treat women based on the results of cervi­
cal length measurement
IV. transfer and treat women based on a combination of 
cervical length measurement and fibronectin measure­
m ent
V. sequential combinations, for example first cervical 
length measurement, and fibronectin measurement in a 
part of that women, or vice versa.
In our cohort, we will obtain data on the m om ent of deliv­
ery in women treated with tocolytics and not treated with 
tocolytics. In addition to our cohort data, we will obtain 
data from medical literature on the occurrence of neonatal 
mortality and morbidity in relation to duration of preg­
nancy, both with and without treatment of corticoster­
oids. We will use this to calculate the expected neonatal 
mortality and morbidity for each of the five strategies 
mentioned above.
Ethical consideration
This study has been approved by the ethics committee of 
the Academic Medical Centre Amsterdam (ref.no MEC 
08/363).
Discussion
In women with clinical signs of threatened preterm labor, 
fibronectin can discriminate between those at low risk 
and high risk for immediate preterm delivery. Since treat­
m ent of low risk women might be unnecessary, testing for 
fibronectin is thought to be a cost effective strategy. It may 
protect m other and fetus from possible side effects of toc- 
olytics and corticosteroids, lessen burden of perinatal
centers and decrease stress and anxiety for the families. So 
far, no randomised trial has shown beneficial effects of 
fibronectin testing for women presenting with threatened 
preterm labor, despite its high negative predictive value. 
Although the use of fibronectin tests for these women is 
already implemented in some clinics and even incorpo­
rated into guidelines [27], neither its safety as a triage 
instrument, nor its cost effectiveness has been established.
We decided to use a fixed protocol to translate the test 
results into a management strategy with nifedipine, to out 
rule the influence of individual physicians. Nifedipine has 
no t yet been tested against placebo as a tocolytic drug, 
though both the Cochrane Collaboration [28] and the 
Dutch Society of Obstetrics and Gynaecology [2] recom­
m end calcium antagonists as first choice. It is unlikely that 
using another tocolytic drug would lead to different out­
comes of this trial, since fibronectin negative women have 
a low a priori probability of delivering within 7 days after 
the test. So even though we randomize on therapy level, 
this trial will evaluate fibronectin testing and cervical 
length measurement for women with threatened preterm 
labor.
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